Fig. 4: WT SARS-CoV-2-specific T cell responses in patients with cancer following vaccination.
a, Exemplar ELISpot illustrating WT SARS-CoV-2-specific T cell responses. PBMCs were stimulated with 15-mer peptide pools spanning the S1 or S2 subunit of the S protein. T cell responses represent the sum of SFU per 106 PBMCs after stimulation with WT S1 or S2 peptide pools. NC, negative control; PC, positive control. b, SFU per 106 PBMCs in infection-naive patients after vaccination (n = 165, 195, 122 and 160 patients at baseline, FU1, FU2 and FU3, respectively). The dotted line at <24 denotes the threshold for positivity. Violin plots denote density; the point range shows the median and 25th and 75th percentiles. Dots represent individual samples. Samples from individual patients are connected. Significance was tested by Kruskal–Wallis test; for the post hoc test, two-sided Wilcoxon–Mann–Whitney U-test with Bonferroni correction was used. Only comparisons with the prior time point are denoted in the graph. Comparison of SFU per 106 PBMCs in patients with (n = 70, 88, 49 and 69 patients at baseline, FU1, FU2 and FU3, respectively) and without prior SARS-CoV-2 infection (n = 165, 195, 122 and 160 patients at baseline, FU1, FU2 and FU3, respectively) (c) and in patients with solid (n = 136, 161, 98 and 130 patients at baseline, FU1, FU2 and FU3, respectively) versus hematological malignancies (n = 29, 34, 24 and 30 patients at baseline, FU1, FU2 and FU3, respectively) (d). Violin plots denote density; the point range shows the median and 25th and 75th percentiles. Dots represent individual samples. Significance in c–d was tested by two-sided Wilcoxon–Mann–Whitney U-test. e, Binary logistic regression of SFU per million PBMCs in patients with solid tumors versus those with hematological malignancies. Dots denote odds ratios (blue, positive odds ratio; red, negative odds ratio); whiskers denote IQR × 1.5. f, Comparison of SFU per million PBMCs in patients with hematological malignancies and solid tumors before the first dose and after the second dose. The dotted line at <24 denotes the lower limit of detection. Violin plots denote density. The point range denotes the median and the 25th and 75th percentiles. Dots represent individual samples. Significance was tested by Kruskal–Wallis test; P < 0.05 was considered significant; for the post hoc test, two-sided Wilcoxon–Mann–Whitney U-test with Bonferroni correction was used. MDS, myelodysplastic syndrome.
